From uncertainty to hope for the future, they offer advice on getting through some of the toughest years of their lives ...

The University of Cebu Lapu-Lapu Mandaue (UCLM) Webmasters lived up to their lofty billing as the defending champions in the ...

CEL-SCI首席执行官Geert Kersten对研究前景表示信心，他提到头颈癌医生的积极反应，以及Multikine有望成为新的治疗标准。虽然 InvestingPro 数据显示公司目前EBITDA为负$24.6M且面临盈利挑战，但生物统计学家建议称，鉴于目标人群的选择基于先前研究中获益最大的群体，该研究成功概率超过95%。投资者可通过 InvestingPro ...

--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced it is in the final stages for the launch of its 212-patient Confirmatory Registration Study for Multikine* (Leukocyte ...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

Chimeric antigen receptor T-cell therapy has been really instrumental in how we treat patients with myeloma. It has really changed the face of how we treat this disease, so since 2021, we've had two ...

此项研究的安全性表现不亚于自体CAR-T疗法，显示出cema-cel的巨大潜力，尤其是在ALPHA3试验中，cema-cel作为LBCL患者巩固疗法的效果正进一步被评估。随着这一新的治疗方案不断得到验证，未来或许能为更多淋巴瘤患者打开新的希望之窗。 返回搜狐，查看更多 ...